Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Authors:
- M. Galán-GangaMGM. Galán-Ganga
- C. Rodríguez-CuetoCRC. Rodríguez-Cueto
- J. Merchán-RubiraJMJ. Merchán-Rubira
- F. HernándezFHF. Hernández
- J. ÁvilaJÁJ. Ávila
- M. Posada-AyalaMPM. Posada-Ayala
- J. L. LanciegoJ. L. Lanciego
- M. G. LopezM. G. Lopez
- A. RábanoA. Rábano
- J. Fernández-RuizJFJ. Fernández-Ruiz
- I. Lastres-BeckerI. Lastres-Becker
Open Access
- 17 May 2021
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 9 (1) , 1-18
Abstract
Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as elements of the endocannabinoid system (ECS). We analysed the occurrence of changes in the ECS in tauopathies and their implication in the pathogenesis. By integrating gene expression analysis, immunofluorescence, genetic and adeno-associated virus expressing TAU mouse models, we found a TAU-dependent increase in CB2 receptor expression in hippocampal neurons, that occurs as an early event in the pathology and was maintained until late stages. These changes were accompanied by alterations in the endocannabinoid metabolism. Remarkably, CB2 ablation in mice protects from neurodegeneration induced by hTAUP301L overexpression, corroborated at the level of cognitive behaviour, synaptic plasticity, and aggregates of insoluble TAU. At the level of neuroinflammation, the absence of CB2 did not produce significant changes in concordance with a possible neuronal location rather than its classic glial expression in these models. These findings were corroborated in post-mortem samples of patients with Alzheimer’s disease, the most common tauopathy. Our results show that neurons with accumulated TAU induce the expression of the CB2 receptor, which enhances neurodegeneration. These results are important for our understanding of disease mechanisms, providing a novel therapeutic strategy to be investigated in tauopathies.Keywords
Funding Information
- Ministerio de Economía y Competitividad (SAF2016-76520-R, PID2019-105600RB-I00, RTI2018-095793-B-I00)
- Research and Innovation of the Community of Madrid (S2017/BMD-3813-ELA_Madrid)
- Research and Innovation of the Community of Madrid ) (B2017/BMD-3827 – NRF24ADCM)
- Fundación Tatiana Pérez de Guzmán el Bueno (P-043-FTPGB 2020)
This publication has 69 references indexed in Scilit:
- Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosisAnnals of Neurology, 2013
- Characteristics of Tau OligomersFrontiers in Neurology, 2013
- Tau and Tauopathies2012
- Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampusNeuropharmacology, 2011
- The dual neuroprotective–neurotoxic profile of cannabinoid drugsBritish Journal of Pharmacology, 2011
- CB2: a cannabinoid receptor with an identity crisisBritish Journal of Pharmacology, 2010
- New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?Nature Reviews Neuroscience, 2010
- The Expression Level of CB1 and CB2 Receptors Determines Their Efficacy at Inducing Apoptosis in AstrocytomasPLOS ONE, 2010
- Knock-out and transgenic mouse models of tauopathiesNeurobiology of Aging, 2009
- Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's diseaseGlia, 2008